In 2009, China's government announced plans to invest RMB1.13 trillion ($180 billion) in expanding and improving healthcare provision, through significant healthcare reforms. These reforms have five key areas of focus:
This massive spending program is rapidly expanding healthcare access for China's 1.3 billion citizens, and has implications for the pharmaceutical industry worldwide.
Inside China's Healthcare Reforms: Opportunities for Multinational Pharma
This comprehensive report goes deep inside China to reveal the ways that recent reforms are changing healthcare for rural and urban citizens. Numerous local experts have been consulted for their insights, including industry experts, government officials, ministry advisers, and formulary managers.
The reader-friendly report explores each key aspect of healthcare reform in turn, clearly explaining what it is, why it was needed, and what progress has been made so far, and then summarising its specific implications for the Pharma industry. As well as covering recent reforms, the report also examines key reform priorities through to 2015.
In addition to a thorough review of reforms and their implications for Pharma, the report provides important insights and tips for building effective relationships with Chinese stakeholders.
Inside China's Healthcare Reforms: Opportunities for Multinational Pharma is a must-have report for anyone with responsibilities or interests in China's healthcare market.
"In terms of the aim to achieve universal [health insurance] coverage, this is already 95%, but the basic benefit package is still quite low. Over the next five years the reimbursement ratio will be increased for the three public insurance programmes for those patients admitted to hospital." - Professor Hu Shanlian of Fudan University (Shanghai), an advisor to the Ministry of Health
"The implementation of universal healthcare has greatly improved the ability of the public to use medical services. Generally speaking, this is conducive to the growth performance of pharmaceutical companies." - Dong Chaohui, vice director, Division of Health Insurance, National Institute for Social Security, MOHRSS
"Once the product is licensed and is on sale in China we try to get onto a provincial list. So you start with one province like Beijing or Shanghai... Once you successfully register the product in one provincial list, you move onto another." - Wai Lun Ng, former CFO, AstraZeneca China